Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Tata Memorial Hospital |
---|---|
Information provided by: | Tata Memorial Hospital |
ClinicalTrials.gov Identifier: | NCT00193726 |
One of the basic principles of cancer chemotherapy is that these drugs act exclusively or mainly on cells in cycle. Estrogens have been shown to increase the fraction of breast cancer cells in cycle. Tamoxifen on the other hand, decreases the proliferative fraction and has been shown to negatively impact on the results of adjuvant chemotherapy in breast cancer when given concomitantly. A number of previous studies have attempted estrogenic recruitment of cancer cells (into cell cycle) to increase the efficacy of chemotherapy in locally advanced and metastatic breast cancer. Although some studies showed an increase in response rates in the recruitment arm, there was no benefit in time to progression or survival in any of the studies. These results may have been due to the inadequate sample size of the studies and advanced stage disease (with presumably higher fraction of inherently chemoresistant cells).
The present study is designed to test the hypothesis that estrogenic recruitment of micrometastatic disease in operable breast cancer will increase the efficacy of standard adjuvant chemotherapy after surgery. The intervention arm of the study will involve administration of short duration estrogen prior to each cycle of adjuvant chemotherapy. The end-points are disease free and overall survival.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: Ethinyl estradiol |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Estrogen Priming to Increase the Efficacy of Standard Adjuvant Chemotherapy in Operable Breast Cancer. |
Estimated Enrollment: | 1400 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | December 2011 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
-
Contact: Sudeep Gupta, MD, DM | + 91 22 24177201 | sudeepgupta04@yahoo.com |
Contact: Rajendra A Badwe, MS | + 91 22 24177000 ext 4264 | tmhcrs@vsnl.com |
India, Maharashtra | |
Tata Memorial Hospital | Recruiting |
Mumbai, Maharashtra, India, 400012 | |
Contact: Rohini Hawaldar + 91 22 24177000 ext 4265 tmhcrs@vsnl.com | |
Contact: Vani Parmar, MS + 91 22 24177194 vparmar@vsnl.net | |
Sub-Investigator: Rajendra A Badwe, MS | |
Sub-Investigator: Reena Nair, MD | |
Sub-Investigator: Vani Parmar, MS |
Principal Investigator: | Sudeep Gupta, MD, DM | Tata Memorial Hospital, Mumbai-400012, India |
Study ID Numbers: | 122 of 2003 |
Study First Received: | September 11, 2005 |
Last Updated: | February 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00193726 History of Changes |
Health Authority: | India: Department of Atomic Energy |
Estrogen Priming Adjuvant chemotherapy Breast cancer |
Estrogens Skin Diseases Hormone Antagonists Estradiol valerate Adjuvants, Immunologic Hormones, Hormone Substitutes, and Hormone Antagonists Breast Neoplasms |
Ethinyl Estradiol Estradiol 17 beta-cypionate Hormones Estradiol Estradiol 3-benzoate Polyestradiol phosphate Breast Diseases |
Estrogens Neoplasms Neoplasms by Site Skin Diseases Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Ethinyl Estradiol Breast Neoplasms Hormones Pharmacologic Actions Breast Diseases |